Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$87.07M-21.4%-$83.87M-28.3%-$79.19M-29.2%-$75.13M-131%-$71.72M-176%
$2.64M+6.6%$2.6M+6.8%$2.55M+5.6%$2.51M+7.3%$2.47M
$6.36M-16.6%$6.82M-2.3%$7.42M+19.8%$7.69M+36.1%$7.63M
-$77.86M-30.2%-$76.75M-39.5%-$76.68M-50.2%-$69.09M-37.6%-$59.79M
$2.32M+104%$2.59M+303%$2.23M+83.7%$1.73M+33.1%$1.14M
$68.76M+157%$63.41M+153%$46.41M+138%-$100.5M-1,361%-$120.27M
-$10.64M+39.5%-$14.52M-9.5%-$30.17M-202%-$5.58M-$17.6M
-$80.18M-31.6%-$79.34M-42.5%-$78.91M-51.0%-$70.81M-37.5%-$60.92M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Artiva Biotherapeutics, Inc. generate?
Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
What is Artiva Biotherapeutics, Inc.'s free cash flow?
After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.